|
The San Francisco Clinical Research Center is one of the leading clinical research centers in the United States. We have been actively
participating in successful clinical trials since 1978. Our headache database, which contains over 5500 patients, has expanded tremendously over the years.
Our site has been involved in landmark studies leading to FDA licensing of all triptan medications marketed thus far, and we are currently
conducting additional studies on three other such medications, as well as new headache treatments and headache prophylactic medications. We have expanded our clinical research center significantly to involve
Alzheimer's prophylaxis and treatment, stroke, acute back pain, anxiety, diabetes, hypertension, post-operative pain, depression and most other neurological conditions.
Our patients are familiar with study requirements and are very compliant. Every patient
receives the highest quality medical care. We notify the patient's primary care physician of enrollment and ongoing status and provide a full report at the conclusion of each study.
We are proud to have a number of sub-specialists, internists and psychologists available to work with us on clinical trials in many other
clinical areas including gastro-enterology, coronary artery disease, genito-urinary disease, hypertension, opthamology, psychiatric disorders, and oncology.
Dr. Jerome Goldstein graduated from the Upstate Medical Center in Syracuse, New York and completed his Neurology residency at the University
of
California in San Francisco in 1970. He is certified by the American Board of Psychiatry and Neurology and is the Director of the San Francisco Clinical Research Center, the San Francisco Headache Clinic and the San Francisco Alzheimer's and Dementia Clinic .
He is an Assistant Clinical Professor of
Neurology at the University of California in San Francisco and is an active member of several organizations including the American Headache Society (AASH), the National Headache Foundation (NHF) and the International Headache Society (IHS).
He is a Fellow member of the American Association for the Study of Headache and the American Academy of Neurology (AAN).
He is the President of the AAN's Headache and Facial Pain Section and Newsletter Editor-in-Chief. He is an active member of the American Academy of Neurology's Section's Committee for Practice Standards and Director of its Annual Course, "Case Studies in Headache".
Dr. Goldstein has directed research studies on every new 5-HT 1D receptor agonists, including the original pilot studies done on
Imitrex® in the United States and has conducted clinical trials on all new prophylactic agents in headache.
Dr.
Goldstein has authored many research publications in the field of
headache. He is a pioneer on multimedia scientific and educational
presentations on pain and headache, especially the general nature
of headache, the comparison of the 5-HT 1D receptor agonists, the
role of opiates in pain and headache management, caffeine in headache
medications and new triptans. Dr. Goldstein is currently pursuing
new research dealing with the meta-analysis of triptans.
Recently,
he has been honored by giving multimedia presentations at the International
Headache Society in Barcelona, Spain; Brazilian Headache Society;
German Pain Congress in Dusseldorf; European Federation of Neurological
Societies in Seville, Spain; XII Migraine International Symposium
in London, England; and 4th Congress of European Headache
Federation in Corfu, Greece. At the International Headache
Society meeting in Armsterdam, Holland, Dr. Goldstein gave a special
salute presentation for those who have contributed instrumentally
to the advancement in the understanding of headache.
|
